Macrophage Subsets in Atherosclerosis|
The diverse range of macrophage phenotypes in atherosclerotic lesions and their potential roles in both plaque progression and stability are discussed, with an emphasis on human pathology. [Nat Rev Cardiol] Abstract
Lessons from Rodent Models in Celiac Disease
The authors review how approaches in rodents have provided insight into celiac disease pathophysiology and also highlight the difficulties met to fully recapitulate the human disease. [Mucosal Immunol] Abstract
Autophagy and Hematopoietic Stem Cell Transplantation
The authors cover established and implicated roles of autophagy in hematopoietic stem cell transplantation, suggesting this pathway as an important therapeutic target for improving transplant outcomes. [Immunol Cell Biol] Abstract
Visit our reviews page to see a complete list of reviews in the immune regulation research field.
Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity|
Lycera Corp. announced that data on the anti-tumor activity of the company’s novel synthetic RORγ agonist product candidates were presented. [Press release from Lycera Corp. discussing research presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, National Harbor] Press Release
Advaxis to Present Survival Data of Lm-LLO Cancer Immunotherapies in Recurrent Cervical Cancer and Canine Osteosarcoma
Advaxis, Inc. announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology. [Press release from Advaxis, Inc. discussing research to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, National Harbor] Press Release
Five Prime Therapeutics Announces Presentation
Five Prime Therapeutics, Inc. announced that it will present a poster describing the use of the company’s protein screening platform to identify unique cancer immunotherapy targets. [Press release from Five Prime Therapeutics, Inc. discussing research to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, National Harbor] Press Release
Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase IIa Clinical Trial Data
Galena Biopharma, Inc. announced that data from the company’s Phase I/IIa trial of GALE-301, a folate binding protein-derived immunotherapy, will be presented. [Press release from Galena Biopharma, Inc. discussing research to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, National Harbor] Press Release
From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.